Transmedics Group (TMDX) closed at $92.01 on November 11, 2026, up 1.2% from the previous close, on volume of 810,912 shares (30-day average 1,072,396).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Double Diagonal | 30-Oct-2664 P : 73 C|06-Nov-2662 P : 70 C | 11,540 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive
Seeking Alpha News (Tue, 10-Nov 12:38 PM ET)
Barclays Reaffirms Their Buy Rating on TransMedics Group (TMDX)
TipRanks (Mon, 9-Nov 4:28 AM ET)
Oppenheimer Keeps Their Hold Rating on TransMedics Group (TMDX)
TipRanks (Sat, 7-Nov 12:35 AM ET)
TransMedics Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 5-Nov 4:02 PM ET)
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
Business Wire (Sun, 1-Nov 4:52 PM ET)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Fri, 30-Oct 4:05 PM ET)
TransMedics to Present at Upcoming Investor Conferences
PRNewswire (Thu, 29-Oct 5:12 PM ET)
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
PRNewswire (Thu, 22-Oct 4:05 PM ET)
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Sat, 26-Sep 1:44 AM ET)
Business Wire (Mon, 14-Sep 2:39 PM ET)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Transmedics Group trades on the NASDAQ stock market under the symbol TMDX.
As of November 11, 2026, TMDX stock price climbed to $92.01 with 810,912 million shares trading.
TMDX has a beta of 0.70, meaning it tends to be less sensitive to market movements. TMDX has a correlation of 0.02 to the broad based SPY ETF.
TMDX has a market cap of $3.20 billion. This is considered a Mid Cap stock.
Last quarter Transmedics Group reported $203 million in Revenue and $.51 earnings per share. This beat revenue expectation by $25 million and exceeded earnings estimates by $.22.
In the last 3 years, TMDX traded as high as $177.37 and as low as $55.00.
The top ETF exchange traded funds that TMDX belongs to (by Net Assets): IJR, VTI, IWM, VB, VBK.
TMDX has underperformed the market in the last year with a return of -24.8%, while SPY returned +12.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in TMDX shares. However, TMDX has outperformed the market in the last 3 month and 2 week periods, returning +4.1% and +32.0%, while SPY returned -1.5% and -1.3%, respectively. This indicates TMDX has been having a stronger performance recently.
TMDX support price is $87.95 and resistance is $93.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TMDX shares will trade within this expected range on the day.
